TY - JOUR AU - Kim, Jayoung AU - Kim, Wun-Jae PY - 2015 TI - Will the 40-gene expression classifier predict responders to EGFR targeted chemotherapy for the invasive bladder cancer patients? JF - Annals of Translational Medicine; Vol 3, No 2 (February 15, 2015): Annals of Translational Medicine Y2 - 2015 KW - N2 - Bladder cancer (BC) is the second most common genitourinary malignancy and the fourth most common cancer in the US, and costs over an estimated $4 billion annually in the US alone. BC ranks amongst the most expensive cancer treatment to date. Most patients have curable transitional cell carcinoma and non-muscle invasive BC (NMIBC). Only approximately 30% of NMIBC patients progress to muscle-invasive BCs (MIBC), however, about 50% of these patients develop metastases within 2 years after cystectomy, and about half of patients die within 5 years. MIBC, which are notorious as heterogeneous and hard-to-treat cancers, do not effectively respond to adjuvant chemotherapy generally associated with a poor prognosis, causing most BC deaths (1). UR - https://atm.amegroups.org/article/view/5490